Tamer Aksoy

Prognostic and Predictive Values of F-18 FDG PET/CT Volumetric Parameters in Small Cell Lung Cancer

Esra Arslan, Göksel Alçın, Tamer Aksoy, Özlem Mermut et autres

Introduction: Volumetric parameters of the 18F-FDG PET/CT can contribute to the treatment decision in high risk patients. In the present study, we aimed to examine the predictive, prognostic, and clinical value of PET/CT by using the two volumetric parameters: metabolic tumor volume …

tr, Somalie (code pays fourni par la source)

[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial

Brian M. Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard, Michael A. Morris et autres

Background With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect clear-cell renal cell carcinoma in patients with renal masses remain an unmet need. 89 Zr-labelled monoclonal antibody ([ 89 Zr]Zr-girentuximab) has high affinity for carbonic anhydrase 9, a tumour …

us, fr, nz, au, be, tr, nl, de (code pays fourni par la source)

The Contribution of 68Ga-FAPI-04 PET/CT to Staging and Prognosis in Gastric Cancer

Ediz Beyhan, Tevfik Fikret Çermik, Özge Erol Fenercioğlu, Rahime Şahin et autres

AIM: This study aimed to compare the diagnostic capabilities of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT imaging in staging gastric carcinoma, exploring the impact of 68 Ga-FAPI-04 PET/CT on treatment planning and its prognostic significance. METHODS: The research included 31 patients …

tr, gb, us (code pays fourni par la source)

[89Zr]Zr-DFO-girentuximab pour l’imagerie par TEP/TDM des cancers du rein à cellules claires – Résultats de l’étude de phase 3 ZIRCON

Brian M. Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard, M. Morris et autres

us, fr, be, nl, au, de (code pays fourni par la source)

68Ga-PSMA PET/CT Found Lower Respiratory Tract Inflammation Due to Inhaler Use

Ediz Beyhan, Tamer Aksoy, Göksel Alçın, Esra Arslan et autres

ABSTRACT: Prostate-specific membrane antigen (PSMA) is a transmembrane protein physiologically expressed in nonprostatic tissues. Inflammation and infectious diseases could show false-positive PSMA uptake. Herein, we present a 55-year-old patient's findings of inflammation in the lower respiratory tract due to inhaler use in …

us (code pays fourni par la source)

TEP/TDM au 89ZR-DFO-Girentuximab pour l’imagerie des carcinomes rénaux à cellules claires–résultats de l’étude de phase III ZIRCON

Jean‐Christophe Bernhard, B. Shuch, Allan J. Pantuck, M. Morris et autres

fr, us, au, be, tr, nl (code pays fourni par la source)

P216 Tracking bone health in paediatric patients with spinal muscular atrophy (SMA)

N. Seçgen, Şulenur Yıldız, Tamer Aksoy, Gökhan Demirkıran et autres

tr (code pays fourni par la source)

68Ga-DOTA-FAPI-04 Imaging of Bilateral Phyllodes Tumor

Göksel Alçın, Esra Arslan, Melis Baykara Ulusan, Tamer Aksoy et autres

ABSTRACT: We present a case of bilateral Phyllodes tumor located in both breasts in a 41-year-old woman who was detected with increased uptake on 68 Ga-FAPI-04 (fibroblast activation protein inhibitor) and 18 F-FDG PET/CT imaging. The tumor filling up the right breast …

kh, tr, ag (code pays fourni par la source)

68Ga-FAPI-04 PET/CT in Selected Breast Cancer Patients With Low FDG Affinity

Göksel Alçın, Esra Arslan, Tamer Aksoy, Merve Cin et autres

PURPOSE: In this prospective study, PET findings of 18 F-FDG PET/CT in breast cancer staging were compared with 68 Ga-FAP inhibitor (FAPI) 04 PET/CT findings in selected cases with relatively low 18 F-FDG uptake in the primary tumor or with suspected nodal …

kh, tr (code pays fourni par la source)

89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study.

Brian M. Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard, Michael J. Morris et autres

4554 Background: Conventional tools (eg, CT, MRI, biopsy) have limitations for characterizing renal mass histology; approx. 25% of patients with an indeterminant renal masses (IDRM) <4cm undergo surgery for benign disease. Accurate noninvasive techniques to risk stratify the IDRM remains an unmet …

us, fr, au, be, tr, nl, de (code pays fourni par la source)

LBA03-01 89 Zr-DFO-GIRENTUXIMAB FOR PET/CT IMAGING OF INDETERMINATE RENAL MASSES–RESULTS FROM PHASE 3 ZIRCON STUDY

Brian M. Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard, Michael A. Morris et autres

You have accessJournal of UrologyCME1 Apr 2023LBA03-01 89Zr-DFO-GIRENTUXIMAB FOR PET/CT IMAGING OF INDETERMINATE RENAL MASSES–RESULTS FROM PHASE 3 ZIRCON STUDY Brian Shuch, Allan J. Pantuck, Jean-Christophe Bernhard, Michael A. Morris, Viraj Master, Andrew Scott, Charles van Praet, Clement Bailly, Bülent Önal, Tamer …

Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).

Brian M. Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard, Michael A. Morris et autres

LBA602 Background: The increasing detection of renal masses presents a significant patient management challenge. Diagnostic options include cross-sectional imaging, which cannot reliably differentiate benign and malignant renal masses, and biopsy, which is invasive and subject to sampling errors. These limitations highlight the …

us, fr, au, be, nl (code pays fourni par la source)